HHS awards $487 million contract to build first U.S. manufacturing facility for cell-based influenza vaccine
The U.S. Department of Health and Human Services (HHS) today announced a $487 million multiple year contract with Novartis Vaccines and Diagnostics, Inc., to build the first U.S. facility to manufacture cell-based vaccine for seasonal and pandemic flu. More >>